BACKGROUND: Pulmonary rehabilitation can improve the functional capacity, but has a variable effect on the low fat-free mass (FFM) in patients with chronic obstructive pulmonary disease. HYPOTHESIS: Pulmonary rehabilitation would not affect catabolic drives such as systemic inflammation and also protein breakdown. METHODS: Patients (n = 40) were studied at the start of an 8-week in-patient pulmonary rehabilitation programme, at the end of the programme and 4 weeks later. FFM and functional capacity (quadriceps strength, handgrip strength and peak workload) were assessed. Pseudouridine (PSU) urinary excretion (cellular protein breakdown) and inflammatory status were determined. Healthy participants had a single baseline assessment (n = 18). RESULTS: PSU, (IL)-6 and soluble tumour necrosis factor (sTNF)alpha R75 were increased in patients compared with healthy participants, whereas FFM and functional capacity were reduced (all p < 0.01). PSU was inversely related to both FFM and skeletal muscle function. FFM and functional parameters increased with rehabilitation, but PSU and inflammatory status were unaffected. The gain in FFM was lost 4 weeks after the completion of rehabilitation (p < 0.01). CONCLUSION: The anabolic effect of pulmonary rehabilitation improved FFM, but it did not reverse the increased protein breakdown or systemic inflammation. Thus, on cessation of pulmonary rehabilitation the FFM gains were lost owing to a loss of anabolic drive.
BACKGROUND: Pulmonary rehabilitation can improve the functional capacity, but has a variable effect on the low fat-free mass (FFM) in patients with chronic obstructive pulmonary disease. HYPOTHESIS: Pulmonary rehabilitation would not affect catabolic drives such as systemic inflammation and also protein breakdown. METHODS:Patients (n = 40) were studied at the start of an 8-week in-patient pulmonary rehabilitation programme, at the end of the programme and 4 weeks later. FFM and functional capacity (quadriceps strength, handgrip strength and peak workload) were assessed. Pseudouridine (PSU) urinary excretion (cellular protein breakdown) and inflammatory status were determined. Healthy participants had a single baseline assessment (n = 18). RESULTS: PSU, (IL)-6 and soluble tumour necrosis factor (sTNF)alpha R75 were increased in patients compared with healthy participants, whereas FFM and functional capacity were reduced (all p < 0.01). PSU was inversely related to both FFM and skeletal muscle function. FFM and functional parameters increased with rehabilitation, but PSU and inflammatory status were unaffected. The gain in FFM was lost 4 weeks after the completion of rehabilitation (p < 0.01). CONCLUSION: The anabolic effect of pulmonary rehabilitation improved FFM, but it did not reverse the increased protein breakdown or systemic inflammation. Thus, on cessation of pulmonary rehabilitation the FFM gains were lost owing to a loss of anabolic drive.
Authors: Annemie M W J Schols; Roelinka Broekhuizen; Clarie A Weling-Scheepers; Emiel F Wouters Journal: Am J Clin Nutr Date: 2005-07 Impact factor: 7.045
Authors: H R Gosker; H van Mameren; P J van Dijk; M P K J Engelen; G J van der Vusse; E F M Wouters; A M W J Schols Journal: Eur Respir J Date: 2002-04 Impact factor: 16.671
Authors: T L Griffiths; M L Burr; I A Campbell; V Lewis-Jenkins; J Mullins; K Shiels; P J Turner-Lawlor; N Payne; R G Newcombe; A A Ionescu; J Thomas; J Tunbridge; A A Lonescu Journal: Lancet Date: 2000-01-29 Impact factor: 79.321
Authors: Mariëlle P K J Engelen; Nicolaas E P Deutz; Rob Mostert; Emiel F M Wouters; Annemie M W J Schols Journal: Am J Clin Nutr Date: 2003-04 Impact factor: 7.045
Authors: Alina A Ionescu; Lisette S Nixon; Stephen Luzio; Vanessa Lewis-Jenkins; William D Evans; Michael D Stone; David R Owens; Philip A Routledge; Dennis J Shale Journal: Am J Respir Crit Care Med Date: 2002-02-15 Impact factor: 21.405
Authors: Eva C Creutzberg; Emiel F M Wouters; Rob Mostert; Clarie A P M Weling-Scheepers; Annemie M W J Schols Journal: Nutrition Date: 2003-02 Impact factor: 4.008
Authors: A A Eid; A A Ionescu; L S Nixon; V Lewis-Jenkins; S B Matthews; T L Griffiths; D J Shale Journal: Am J Respir Crit Care Med Date: 2001-10-15 Impact factor: 21.405
Authors: Alvar G N Agustí; Jaume Sauleda; Cristina Miralles; Cristina Gomez; Bernat Togores; Ernest Sala; Santiago Batle; Xavier Busquets Journal: Am J Respir Crit Care Med Date: 2002-08-15 Impact factor: 21.405
Authors: Tomas M L Eagan; Esteban C Gabazza; Corina D'Alessandro-Gabazza; Paloma Gil-Bernabe; Shinya Aoki; Jon A Hardie; Per S Bakke; Peter D Wagner Journal: Respir Res Date: 2012-06-18
Authors: Nichola S Gale; James M Duckers; Stephanie Enright; John R Cockcroft; Dennis J Shale; Charlotte E Bolton Journal: BMC Pulm Med Date: 2011-04-21 Impact factor: 3.317
Authors: Eloisa Sanches Pereira do Nascimento; Luciana Maria Malosá Sampaio; Fabiana Sobral Peixoto-Souza; Fernanda Dultra Dias; Evelim Leal Freitas Dantas Gomes; Flavia Regina Greiffo; Ana Paula Ligeiro de Oliveira; Roberto Stirbulov; Rodolfo Paula Vieira; Dirceu Costa Journal: Int J Chron Obstruct Pulmon Dis Date: 2015-03-23
Authors: Jana De Brandt; Martijn A Spruit; Dominique Hansen; Frits Me Franssen; Wim Derave; Maurice Jh Sillen; Chris Burtin Journal: Chron Respir Dis Date: 2017-06-05 Impact factor: 2.444